Amygdala Neurosciences, Inc.
Records under this name other than the patents Amygdala Neurosciences, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 7 patents it holds.
Showing 1 to 5 of 5 · Back to Amygdala Neurosciences, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,673,966 | ALDH-2 Inhibitors in the Treatment of Addiction Lapsed on the fee record Ended Mar 18, 2026 · High confidence | Lapsed on the fee record | Ended Mar 18, 2026 | High confidence |
| US 9,610,299 | Compounds for the Treatment of Addiction Lapsed on the fee record Ended Apr 4, 2025 · Medium confidence | Lapsed on the fee record | Ended Apr 4, 2025 | Medium confidence |
| US 8,158,810 | ALDH-2 Inhibitors in the Treatment of Addiction Lapsed on the fee record Ended Apr 17, 2024 · Low confidence | Lapsed on the fee record | Ended Apr 17, 2024 | Low confidence |
| US 10,507,215 | Compounds for the Treatment of Addiction Lapsed on the fee record Ended Dec 17, 2023 · High confidence | Lapsed on the fee record | Ended Dec 17, 2023 | High confidence |
| US 7,951,813 | Quinazolinone Derivatives as ALDH-2 Inhibitors Lapsed on the fee record Ended May 31, 2023 · High confidence | Lapsed on the fee record | Ended May 31, 2023 | High confidence |